PACE: 1- and 5-year response at any time in patients with CP-CML, overall, and in patients resistant/intolerant to previous treatment with dasatinib or nilotinib or with T315I mutation (adapted from [6, 10]). R/I resistant or intolerant; MCyR, major cytogenetic response; CCyR, complete cytogenetic response; MMR, major molecular response; MR4.5, 4.5-log reduction or ≤0.0032% BCR-ABL.